Skip to main content

Market Overview

Why Did Ocugen Stock Skyrocket On Monday?

Share:
Why Did Ocugen Stock Skyrocket On Monday?

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session.

What Happened: Ocugen’s shares rallied on Monday despite no company-specific news. The stock could have gained amid some positive news related to its COVID-19 vaccine partner, India-based Bharat Biotech.

The stock is also seeing high interest from retail investors and is the eighth-most discussed stock on Reddit’s r/WallStreetBets forum as of Monday night, as per data from Quiver Quantitative.

The World Health Organization (WHO) is likely to soon approve Bharat Biotech’s COVID-19 vaccine, Covaxin, for emergency use, according to a report by India Today.

Meanwhile, a report by News18 said that a subject expert committee of India’s national regulatory body for pharmaceuticals and medical devices would decide on Bharat Biotech’s pediatric COVID-19 vaccine later on Monday.

Bharat Biotech will also produce part of the world’s only malaria vaccine developed by pharma major GlaxoSmithKline plc (NYSE: GSK) and recently approved by the WHO, as per a report by the Hindustan Times.

Price Action: Ocugen’s shares closed 8.8% higher in Monday’s regular trading session at $7.69 and further rose 11.4% in the after-hours session to $8.57.

Read Next: AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial

 

Related Articles (OCGN)

View Comments and Join the Discussion!

Posted-In: Bharat Biotech CovaxinBiotech News Small Cap Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com